[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oric Pharmaceuticals insider transactions by CFO Dominic Piscitelli show a simultaneous option exercise and sale on 10/06/2025. The filing reports exercise of 11,000 stock options at an exercise price of $4.36 per share, resulting in immediate acquisition of 11,000 common shares. Those 11,000 shares were sold under a Rule 10b5-1 plan at a weighted average price of $14.5199 per share, completing sales in the $14.50–$14.53 range and leaving the reporting person with 48,317 shares outstanding directly. After the transactions, the reporting person holds 196,500 shares subject to outstanding options. The sale was executed pursuant to a trading plan adopted on 06/24/2025.

Positive

• Use of a Rule 10b5-1 trading plan adopted on 06/24/2025 provides procedural defensibility for the sales
• Realized proceeds per share were materially above exercise price: sold at a weighted average of $14.5199 vs exercise at $4.36

Negative

• Net direct holdings decreased from 59,317 to 48,317 shares after the sale
• Significant remaining option exposure of 196,500 shares outstanding could lead to future dilution if exercised

Insights

Corporate Insider Transactions Analyst

Simultaneous option exercise and planned sale shows routine liquidity event, not a disclosed judgment on value.

The reporting person exercised 11,000 stock options at an exercise price of $4.36 and sold those same shares under a Rule 10b5-1 plan for a weighted average of $14.5199. This sequence converted vested option value to cash while retaining direct ownership of 48,317 shares and holding options for 196,500 underlying shares.

Risks include potential market perception when an officer sells shares; however, the existence of a pre-established 10b5-1 plan (adopted 06/24/2025) reduces concerns about opportunistic timing. Monitor future Form 4 filings for additional sales or exercises and any amendments to trading plans within the next 12 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		M		11,000	A	$4.36	59,317	D
Common Stock	10/06/2025		S(1)		11,000	D	$14.5199(2)	48,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	10/06/2025		M			11,000	07/20/2025	07/19/2032	Common Stock	11,000	$0	196,500	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.

2. Represents the weighted average share price of an aggregate total of 11,000 shares sold in the price range of $14.50 to $14.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Oric Pharmaceuticals CFO Dominic Piscitelli do on 10/06/2025 (ORIC)?

The CFO exercised 11,000 stock options at $4.36 and sold those 11,000 shares under a Rule 10b5-1 plan for a weighted average of $14.5199 per share.

How many ORIC shares does the reporting person own after the reported transactions?

After the transactions the reporting person directly owns 48,317 common shares.

What trading plan governed the sale of ORIC shares?

The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/24/2025.

What was the price range for the ORIC shares sold and the weighted average sale price?

Shares were sold in the range of $14.50 to $14.53, with a weighted average sale price of $14.5199.

How many ORIC shares remain under option for the reporting person?

The filing shows 196,500 shares underlying outstanding options held by the reporting person.